

ASX Announcement

11 June 2026

ReNerve appoints J4 as second Empliq™ manufacturing partner to meet growing market demand

Key Highlights

- ReNerve executes supply partnership agreement with Texas-based J4 as a second approved manufacturer of its Empliq™ product range
- Partnership driven by accelerating commercial traction and increased market demand
- Dual-supplier strategy strengthens supply chain resilience and scales manufacturing capacity to support growth
- With several recent new hospital approvals for Empliq, the partnership enables ReNerve to fulfil expanding order volumes and shorten lead times for customers
- Appointment reflects ReNerve's confidence in Empliq's™ commercial trajectory and its commitment to meeting market demand

ReNerve Limited (ASX, "ReNerve" or "the Company"), an Australian biotechnology company developing innovative products for peripheral nerve injury ("PNI") repair, is pleased to announce it has entered into a product supply partnership agreement with J4 Biologics LLC (J4), headquartered in San Antonio, Texas, for the manufacture of its proprietary Empliq™ product range.

J4 has been appointed as ReNerve's second approved manufacturing partner, alongside the Company's existing supplier, as ReNerve continues to scale its commercial operations in response to growing demand.

As Empliq™ continues to gain meaningful market traction across its target customer segments, ReNerve has identified the need to secure additional manufacturing capacity to reliably meet accelerating demand. The appointment of a second qualified supplier is a deliberate and proactive step to:

- Increase total manufacturing output to align with current and anticipated order volumes
- Ensure supply chain continuity and reduce concentration risk across the production network
- Shorten lead times and improve product availability for existing and new customers
- Establish a scalable manufacturing infrastructure capable of supporting the Company's longer-term commercial ambitions

This strategic move reflects the Board's confidence in the commercial outlook for Empliq™ and the Company's commitment to building an operationally robust business capable of servicing the market at scale.

J4 is an experienced manufacturing partner with demonstrated capability in the production of specialised life science and medical-related products. ReNerve appointed J4 following a rigorous



+61 (03) 9482 3940



157 Heidelberg Rd,
Northcote, VIC 3070



www.renerve.com.au

qualification and evaluation process where it met the Company's quality, compliance, and production standards.

Under the terms of the partnership, J4 will manufacture Empliq™ inventory to ReNerve's specifications, providing the Company with additional production throughput to supplement its existing manufacturing arrangements. The agreement is structured to allow flexible scaling of inventory production in line with commercial demand signals.

"Securing a secondary supplier of our Empliq product range is essential to ReNerve, especially as we gain more hospital approvals and see a growing demand for our products. We are delighted to be working with the team at J4 given their expertise and experience in the industry" said ReNerve CEO Dr Julian Chick.

ReNerve will continue to manage its supply chain and manufacturing partnerships proactively to ensure it can meet market demand as the Empliq™ commercial programme scales. The Company expects the additional manufacturing capacity provided through its partnership with J4 to become operational in the near term, with initial inventory production anticipated to commence shortly following completion of onboarding and quality assurance processes.

Key Terms of the agreement are:

- The agreement has an initial term of three years, with automatic renewal for additional two-year periods unless terminated.
- The arrangement is non-exclusive.
- The Company is subject to minimum annual purchase commitments, commencing at approximately 500 units in the first year, increasing in subsequent years.
- Either party may terminate the agreement for material breach, certain insolvency events, or without cause on 60 days' notice.
- Pricing is agreed for an initial 12-month period and may be varied thereafter on notice.

The Company does not expect the agreement to have a material impact on its financial performance in the near term.

The Board and management team remain focused on executing ReNerve's commercial strategy and will provide further updates on sales progress and supply chain developments as appropriate.

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au


About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through **breakthrough medical technology**. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comparison of Patient Pre & Post Surgery Pain Score



Standard of Care vs NervAlign™ Nerve Cuff Protected Nerve Repairs

The comparison of pain scores between the two cohorts of patients

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions and related surgical repairs:

On market

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Empliq™ Deep Dermal tissue product** -- A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Empliq™ Amniotic tissue product ranges** -- Three amniotic tissue product ranges used to aid the healing of wounds.

In development

- **NervAlign® Nerve Conduit Range** – Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching \$271k in sales and YTD FY2026 sales revenues showing further significant increases across its portfolio. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US\$1.6 billion in 2024 and is projected to reach \$6.2 billion by 2031.¹

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

About J4 Biologics, LLC

Overview

J4 Biologics is a San Antonio-based human tissue processor founded in 2022. The company specializes in the ethical, high-quality manufacturing of amnion and dermal products. Its products are used in hospitals and clinics across the United States and are known for their superior handling and feel.

¹ Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)